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S U M M A R Y
Objective: To characterize Bordetella pertussis isolates in Ontario, Canada in order to understand the
clonal diversity of strains present in this province.
Methods: A total of 521 isolates from the period 1998–2006 were analyzed by serotyping, pulsed-ﬁeld
gel electrophoresis (PFGE), and DNA sequencing of their virulence factors of pertactin, ﬁmbriae 3,
pertussis toxin subunit 1, and pertussis toxin gene promoter. Characteristics of the Ontario isolates were
compared to those described for isolates from Europe and Australia.
Results: A single predominant clone was identiﬁed in Ontario, Canada, represented by 83.5% of the 521
isolates analyzed. This clone was characterized by the genotype ﬁm3B, prn2, ptxS1A, and ptxP3 (sequence
type (ST)-1), and 72.9% of this clone displayed three closely related PFGE proﬁles of BpSR11, BpSR5, and
BpSR12. Pertussis isolates in Europe with these PFGE proﬁles and virulence factor genotype are reported
as common. The Australian epidemic clone was previously reported to have the genotype prn2 and ptxP3.
Conclusion: The ﬁnding of one predominant B. pertussis clone in Ontario, Canada, with characteristics
identical to strains involved in epidemics in Europe and Australia, suggests a potential link of this strain
to the resurgence of pertussis in this province.
Crown Copyright  2013 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
Contents lists available at SciVerse ScienceDirect
International Journal of Infectious Diseases
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Pertussis or whooping cough is caused by the strict human
pathogen Bordetella pertussis. Current laboratory methods for the
diagnosis of pertussis include culture on specialized media, PCR,
and serology. Each of these approaches has its merits and
limitations, but due to difﬁculties in culturing B. pertussis, most
cases of pertussis in Canada are now diagnosed by PCR.1,2
Pertussis became a nationally notiﬁable disease in Canada in
1924, with the highest incidence rates reported between 1934 and
1943.3 The introduction of the whole cell pertussis vaccine in 1944
resulted in a drop in incidence rates by over 50% within the ﬁrst
decade and a steady decrease in each passing decade with an all-
time low in the mid-1980s.3 Acellular pertussis vaccines were
introduced in Canada in 1997–1998, and despite high vaccine
coverage, there have been reports of pertussis outbreaks and
increased disease activity over the last two decades.1,4,5 This* Corresponding author. Tel.: +1 204 789 6020; fax: +1 204 789 2018.
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http://dx.doi.org/10.1016/j.ijid.2012.12.015resurgence of pertussis is thought to be due to a combination of
reasons: (1) age-speciﬁc contact patterns;6 (2) waning immunity
in vaccinated individuals; (3) better detection methods, including
the use of PCR to positively identify cases; (4) increased awareness,
and (5) the evolution of the bacterium resulting in new emerging
clones.7–9
Antigenic variations involving the virulence antigens present in
the vaccines have been noted over the years, particularly pertactin
and pertussis toxin subunit 1, encoded by the genes prn and ptxS1,
respectively.10 Strains recovered prior to 1970 often express ptxS1B
and prn1 alleles, while strains characterized by ptxS1A and either
prn2 or prn3 appeared in the mid-1980s after vaccine programs
had been introduced.10 Another notable change in the B. pertussis
bacterium is the recent ﬁnding of strains that express increased
levels of pertussis toxin caused by a mutation in the pertussis toxin
gene promoter designated by the allele ptxP3.11 The prevalence of
strains expressing the ptxP3 allele went from 0% in 1989 to 100% in
2004 in the Netherlands.11 Patients infected with ptxP3 strains had
increased incidence of hospitalization, deaths, and lethality (ratio
of deaths to hospitalizations), thus suggesting an increased
virulence of such strains.Ltd on behalf of International Society for Infectious Diseases. All rights reserved.
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atypical pertussis occurred in the city of Toronto, in the province of
Ontario in Canada, involving 313 fully immunized pre-school
children between the ages of 1 and 4 years.2 The majority of cases
were diagnosed by PCR and only ﬁve were positive by culture. Due
to the lack of positive cultures from the outbreak, we analyzed a
large sample of B. pertussis isolates recovered in 2004–2005 just
prior to the outbreak, as well as from the earlier years of 1998–
2003, in order to understand the characteristics of the strains in
Ontario leading up to this atypical outbreak. A total of 521 strains
were serotyped, and partial gene sequences of the virulence factors
pertactin, ﬁmbriae 3, pertussis toxin subunit 1, and pertussis toxin
gene promoter region were determined together with pulsed-ﬁeld
gel electrophoresis. The objective of this study was to characterize
B. pertussis isolates in Ontario, Canada in order to understand the
clonal diversity of strains present in this province.
2. Materials and methods
2.1. Bacterial strains
B. pertussis were isolated from nasopharyngeal specimens on
charcoal agar with 5% horse blood with and without cephalexin,
and identiﬁed by standard methods.12 The distribution of isolates
analyzed over the period of this study is described in Table 1.
2.2. Serotyping
Serotyping was performed by the indirect whole cell ELISA
method, as previously described,13 using monoclonal antibodies to
the ﬁmbriae 2 and 3 antigens (gifts from Dr Dorothy Xing, National
Institute for Biological Standards and Control, UK).
2.3. DNA sequencing
PCR and partial gene sequencing was performed using the
primers and conditions previously described for the following
virulence genes: pertussis toxin subunit S1 (ptxS1), pertactin
region 1 (prn),14 ﬁmbriae 3 (ﬁm3),15 and the pertussis toxin gene
promoter region (ptxP).11 PCR products were puriﬁed using the
Qiagen QIAquick PCR Puriﬁcation Kit (Mississauga, ON, Canada)
and sequenced using an ABI Prism 377 DNA sequencing system
(Applied Biosystems, Foster City, CA, USA). Sequences were
analyzed using DNASTAR software (DNASTAR Inc., Madison, WI,
USA). Isolates were assigned sequence types (STs) according to the
combination of alleles of these antigen genes present (see footnote
of Table 1).Table 1
Temporal distribution of sequence types of 521 Bordetella pertussis isolates collected in
Year of isolation Number of isolates Sequence typesa
ST-1 ST-2 ST-5 ST-6
1998 4 4
1999 41 38 2 
2000 28 27 1
2001 27 21 6
2002 44 35 5 3 
2003 31 24 4 
2004 174 152 14 1 
2005 120 90 18 1 
2006 1 1
Unknown 51 43 7 
All 521 435 57 2 3 
a ST-1: prn2, ﬁm3B, ptxS1A, ptxP3; ST-2: prn2, ﬁm3A, ptxS1A, ptxP3; ST-5: prn1, ﬁm3A*, p
prn9, ﬁm3B, ptxS1A, ptxP3; ST-9: prn15, ﬁm3B, ptxS1A, ptxP3; ST-10: prn2, ﬁm3E, ptxS1A, pt
ﬁm3B, ptxS1A, ptxP15.2.4. Pulsed-ﬁeld gel electrophoresis (PFGE)
PFGE was performed using XbaI and SpeI restricted genomic
DNA, as previously described,16 on the CHEF-DR III system (Bio-
Rad Laboratories, Mississauga, ON, Canada) for 18 h at 14 8C, with
switch times of 2.2–35.1 s and linear ramping. The resulting DNA
ﬁngerprint proﬁles were analyzed using BioNumerics (Applied
Maths, Austin, TX, USA) with a band tolerance of 1% and
optimization setting of 1%, and grouped according to reference
proﬁles.17,18 The following reference strains were used: CCUG
30873 (group I); Tohama I (group II); B902 (group IVa), and Fr287
(group V). Strains representing proﬁles from group IVa (BpSR10,
BpSR19, and BpSR147) and group IVb (BpSR5, BpSR11, and
BpSR12) were obtained from Dr Hans Hallander at the National
Institute for Public Health and the Environment (RIVM) in Sweden.
3. Results
3.1. Serotype antigens and genotypic proﬁle of virulence antigen
genes
Fimbriae serotype 3 antigens were detected in 519 or 99.6% of
the 521 isolates analyzed, including two that expressed both Fim2
and Fim3 antigens. One isolate expressed exclusively Fim2 antigen,
while in another isolate, ﬁmbriae antigen was not detected.
The majority (95.2%, n = 496) of the isolates analyzed expressed
the pertactin genotype prn2, while 3.8% (n = 20) expressed prn3
and the remaining 1% (n = 5) were prn1 (n = 3), prn9 (n = 1), or
prn15 (n = 1) (GenBank accession number JX100834). Four
hundred ﬁfty-seven isolates or 87.7% expressed the ﬁm3B
genotype, while 63 isolates or 12.1% expressed ﬁm3A (n = 61) or
ﬁm3A*(n = 2), which is identical to ﬁm3A with the exception of a
single synonymous mutation,15 and one isolate possessed a new
genotype, ﬁm3E (GenBank accession number JX100833). Pertussis
toxin subunit 1 allele ptxS1A was found in the majority of the
isolates (99.6%, n = 519), with only one isolate being ptxS1B, and
the remaining isolate with a new genotype ptxS1H (GenBank
accession number JX100836). For the pertussis toxin gene
promoter region, ptxP3 was the predominant allele, found in
98.5% of the strains (n = 513), while only six isolates or 1.2%
expressed ptxP1 allele and two isolates expressed the ptxP15 allele.
Based on genetic variations of these virulence antigen genes,
one major sequence type was identiﬁed, which consisted of 435
isolates or 83.5%, and was assigned to ST-1, which was
characterized by the genotype of prn2, ﬁm3B, ptxS1A, and ptxP3.
Two other common STs were ST-2 (10.9%, n = 57, characterized by
prn2, ﬁm3A, ptxS1A, and ptxP3) and ST-7 (3.3%, n = 17, characterized Ontario, Canada, 1998–2006
 ST-7 ST-8 ST-9 ST-10 ST-11 ST-12 ST-16
1
1
3
4 1 1 1
10 1
1
17 1 1 1 1 1 2
txS1A, ptxP1; ST-6: prn3, ﬁm3A, ptxS1A, ptxP1; ST-7: prn3, ﬁm3B, ptxS1A, ptxP3; ST-8:
xP3; ST-11: prn1, ﬁm3A, ptxS1B, ptxP1; ST-12: prn2, ﬁm3B, ptxS1H, ptxP3; ST-16: prn2,
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Figure 1. Comparison of the different PFGE proﬁles for 435 Bordetella pertussis strains belonging to ST-1, 57 strains belonging to ST-2, and 17 ST-7 strains. Groupings are
shown based on reference proﬁles BpSR11*, BpSR5y, BPSR12z, and BpSR10§.19
M. Shuel et al. / International Journal of Infectious Diseases 17 (2013) e413–e417 e415by prn3, ﬁm3B, ptxS1A, and ptxP3). The remaining 12 isolates were
grouped into eight different STs (Table 1).
When analyzed against the year of isolation, at least 75% of the
isolates obtained from each of the years covering 1998–2006belonged to ST-1. In contrast, isolates that belonged to ST-7 were
found only after 2002; of the 144 isolates examined for 1998–2002,
none belonged to ST-7, but 17 (5%) of the 326 isolates of 2003–
2006 belonged to ST-7.
M. Shuel et al. / International Journal of Infectious Diseases 17 (2013) e413–e417e4163.2. Clonal analysis by PFGE
Figure 1 shows the PFGE proﬁles of the 509 B. pertussis strains
belonging to ST-1, ST-2, and ST-7. PFGE analysis of the ST-1 isolates
conﬁrmed the presence of one major clonal type with PFGE proﬁles
that belonged to PFGE group IVb (98.4%, n = 428), with 51.2%
(n = 219) expressing a single proﬁle identical to the European
proﬁle BpSR11.19,20 Although the 428 isolates in group IVb gave 43
different PFGE proﬁles with an overall similarity of 81.3%, there
were four highly related proﬁles with >94% similarity present in
80.6% of the isolates (n = 345). Three of these four highly related
proﬁles were identical to proﬁles commonly found in B. pertussis
isolates from Europe (BpSR11, BPSR5, and BpSR12).19,20 Of the
remaining seven ST-1 isolates with PFGE proﬁles that did not
belong to group IVb, three gave proﬁles that belong to group IVa.
PFGE proﬁles did not cluster into any known groups for the other
four isolates.
The other two common STs differentiated by the characteristics
of ﬁm3A (ST-2) and prn3 (ST-7) were mostly in the PFGE groups of
IVa or IVb, respectively. Fifty-ﬁve of the 57 ST-2 isolates were
deﬁned by PFGE as group IVa and showed 15 different PFGE
proﬁles, with an overall similarity of 87.7%. Fifteen of the 17 ST-7
isolates were grouped by PFGE as group IVb, with 10 isolates
showing proﬁles identical to BpSR5, and ﬁve isolates with proﬁles
closely related to BpSR5 (identical XbaI restriction pattern but with
a different SpeI pattern when compared to BpSR5).
4. Discussion
In the city of Toronto, Ontario, Canada, an atypical pertussis
outbreak occurred between October 2005 and March 2006, which
coincided with a more than two-fold increase in the number of
respiratory specimens that tested positive for pertussis by PCR.2 A
subsequent retrospective study over a longer period of time, from
1993 to 2007, conﬁrmed a true increase in pertussis disease
activity in the city of Toronto, despite an increase in the utilization
of laboratory testing for pertussis especially by PCR since 2005 and
the improved sensitivity of this molecular testing.21
Since most laboratory conﬁrmed cases of pertussis are now
detected by PCR, the number of cases with positive bacterial
cultures is relatively small, as exempliﬁed by the Toronto outbreak
in October 2005 to March 2006. Therefore, to gain insights into the
clonal dynamics of the pertussis population in the most populous
province in Canada, we analyzed 521 B. pertussis isolates collected
from 1998 to 2006 with over 50% of the samples collected in the
years 2004–2005.
In this study, we found that 82% of the 521 isolates examined
belonged to one clonal type characterized by the genotype prn2,
ﬁm3B, ptxS1A, and ptxP3 (ST-1), and PFGE group IVb. Furthermore,
51% of this clone expressed one PFGE proﬁle designated as BpSR11,
which has been observed as the predominant proﬁle found in a
number of European countries, especially in Sweden and
Finland.19,20,22 Strains with this proﬁle were found in 30–50% of
B. pertussis isolates examined in ﬁve of eight European countries
(Finland, France, Sweden, Germany, and the Netherlands).20 In
addition, strains expressing the BpSR11 PFGE proﬁle have been
suggested to cause more severe disease,23 and have the potential
for widespread distribution.24 Besides BpSR11, two other closely
related PFGE proﬁles, BpSR5 and BpSR12,25 were also found among
Ontario isolates, with frequencies of 11.3% and 9.6%, respectively.
Therefore, 317 of the 435 ST-1 isolates (72.9%) in Ontario, Canada
expressed three closely related PFGE proﬁles of BpSR11, BpSR5,
and BpSR12.
B. pertussis isolates in Sweden with the BpSR11 PFGE proﬁle
have been characterized to possess ptxS1A, prn2, and ﬁm3B.25 A
strong linkage between the BpSR11 PFGE proﬁle and the ptxP3genotype has also been described among the European B. pertussis
isolates.24 This study conﬁrmed that the linkage involving BpSR11
PFGE proﬁle and the ptxP3 genotype also exists among the Ontario
isolates. However, unlike genotyping that targets certain genes,
PFGE has a higher discriminatory power with the ability to type all
isolates, while genotyping based on PCR and subsequent sequenc-
ing may fail due to either complete absence of target genes or
nucleotide variations in primer sites designed to amplify the target
genes. Furthermore, PFGE analyses the whole genome rather than
select genes. A comparison of three typing methods conﬁrmed that
PFGE is superior to multilocus sequence typing and multilocus
variable number tandem repeat analysis.24
Although isolates from the ﬁve culture-positive cases of the
atypical pertussis outbreak in Toronto, Ontario, involving fully
immunized pre-school children may not be included in this study,
the presence of a predominant B. pertussis clone with prn2 and
ptxP3 in the years immediately prior to the outbreak suggests a
potential causal relationship of this clone in the outbreak.
Furthermore, the virulence characteristics of prn2, ptxS1A, and
ptxP3 present in the Ontario clone have also been associated with
pertussis epidemics in other countries,10,11,17,20,22,24,25 which adds
further evidence to support the potential involvement of this clone
in the Toronto outbreak. B. pertussis strains with the ptxP3
mutation produce increased amounts of pertussis toxin, which
have been shown to enhance transmission of pertussis via
suppression of the immune response.26,27 The increased amount
of pertussis toxin produced by these strains might contribute
towards the ability of this clone to partially overcome immunity
induced by pertussis vaccination, thus allowing milder symptoms
to occur in affected individuals, as in the cases of the Toronto
outbreak in 2005–2006. Up-regulation of virulence factors has also
been shown in two other vaccine-preventable bacterial disease
agents, Haemophilus inﬂuenzae serotype b and serogroup C
Neisseria meningitidis.28,29 B. pertussis strains with the prn2
genotype have also been described to have a selective survival
advantage in vaccinated populations.30,31 The adaptation of B.
pertussis to vaccine immunity as evidenced by the genetic
polymorphisms displayed by circulating strains warrants moni-
toring for changes in the strain type in a vaccinated population.
Current studies in our laboratories include continuing to monitor
any changes in the prevalence of the different STs deﬁned in this
study, including ST-1, the predominant clone, and ST-7, which
emerged after 2002, as well as identifying other genetic and/or
phenotypic markers that are associated with strains expressing a
selective advantage over others in a vaccine-induced pressure
environment.
In conclusion, the data presented suggest a predominant clone
of B. pertussis circulating in the province of Ontario. The
characteristics of this clone are similar to the clone that is
prevalent in many European countries17,20,22,24 and the recently
described emerging clone that caused a pertussis epidemic in
Australia.32
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